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Background: Randomised controlled trials (RCTs) are the gold standard assessment for health technologies. A key
aspect of the design of any clinical trial is the target sample size. However, many publicly-funded trials fail to reach
their target sample size. This study seeks to assess the current state of recruitment success and grant extensions in
trials funded by the Health Technology Assessment (HTA) program and the UK Medical Research Council (MRC).
Methods: Data were gathered from two sources: the National Institute for Health Research (NIHR) HTA Journal
Archive and the MRC subset of the International Standard Randomised Controlled Trial Number (ISRCTN)
register. A total of 440 trials recruiting between 2002 and 2008 were assessed for eligibility, of which 73 met the
inclusion criteria. Where data were unavailable from the reports, members of the trial team were contacted to
ensure completeness.
Results: Over half (55%) of trials recruited their originally specified target sample size, with over three-quarters
(78%) recruiting 80% of their target. There was no evidence of this improving over the time of the assessment.
Nearly half (45%) of trials received an extension of some kind. Those that did were no more likely to successfully
recruit. Trials with 80% power were less likely to successfully recruit compared to studies with 90% power.
Conclusions: While recruitment appears to have improved since 1994 to 2002, publicly-funded trials in the UK
still struggle to recruit to their target sample size, and both time and financial extensions are often requested.
Strategies to cope with such problems should be more widely applied. It is recommended that where possible
studies are planned with 90% power.
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This study seeks to assess the current state of recruit-
ment success and grant extensions in trials funded by
the UK Health Technology Assessment (HTA) program
and the UK Medical Research Council (MRC). This
work updates a review for the interval 1994 to 2002 by
McDonald et al. [1].
When planning a trial, one essential step is the calcu-
lation of a sample size that will give the minimum num-
ber of participants required to meet the objectives of the
study [2].* Correspondence: s.a.julious@sheffield.ac.uk
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reproduction in any medium, provided the orHaving a good estimate of the sample size is import-
ant, as studies that are either too small or too large may
be judged unethical [3]. For example, a study that is too
large could have met the objectives of the trial before
the actual study end had been reached, meaning that
some patients may have unnecessarily entered into the
trial and been randomised to a therapy that can be
proven to be suboptimal. Conversely, a trial that is too
small may have little chance of meeting the study objec-
tives, and patients may be entering a trial for no tangible
benefit.
Poor recruitment is acknowledged as an important
shortcoming of many randomised controlled trials (RCTs),
which can prevent a study from reaching its target sample
size [1,4,5]. Of trials published in the British Medicald. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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51% of multicentered trials reported difficulties in recruit-
ment [6], while a 2006 review of publicly-funded multi-
center trials found that less than a third of all studies
achieved their recruitment target and half of all studies re-
ceived an extension [1].
The consequences of poor recruitment are varied. If
the target sample size is not met then the chances of
seeing a statistically significant result when there is a
true difference between treatments will be reduced,
therefore decreasing the likelihood of finding evidence
of an effect for a particular health technology.
Poor recruitment also has a negative impact on a trial’s
costs: if an extension is required to obtain the target
sample size, the trial’s budget will be increased.
While the issue is not new, there is little quantitative
research on the extent of the problem. This review
aims to update research funded by the UK National
Health Service (NHS) R&D National Methodology
Programme and the UK MRC in 2006, which looked at
recruitment to publicly-funded multicenter trials be-
tween 1994 and 2002 [1]. In this study, we update this
review to look at studies undertaken between 2002
and 2008.Figure 1 Flow diagram for the study.Methods
Trial identification
We looked at 73 trials funded by the HTA and the UK
MRC. Data were collected from the online databases
held by the bodies: the MRC subset of the Current Con-
trolled Trials metaregister (http://www.controlled-trials.
com/mrct/), and the HTA archive of published articles
(http://www.hta.ac.uk/project/htapubs.asp). Inclusion and
exclusion criteria were chosen to match the previous study
[1]. Trials were eligible if: (1) they were multicenter (multi-
center trials are commonly reported to recruit more slowly
than expected [7]), (2) recruitment started on or after 1
January 2002, (3) recruitment was originally planned to
close on or before 31 December 2008 (trials that were
awarded an extension beyond 31 December 2008 were
included if they had closed to recruitment when data
were extracted), and (4) they were not a cluster
randomised trial (these were excluded because recruit-
ment issues differ).
These criteria were chosen to be consistent with
McDonald et al. [1] to ensure comparability. Note
that there is no overlap between these two pieces of
research: the previous study required trials to have
finished recruiting by 1 January 2002, and ours
Table 1 Characteristics of trials
Characteristic 1994 to 2002 2002 to 2008
N n (%) N n (%)
What type of trial design was used? 122 73
Parallel 113 (93) 66 (90)
Factorial 6 (5) 4 (5)
Partially randomised patient
preference
3 (2) 3 (4)
How many arms were there
in the trial?
122 73
Two 94 (77) 53 (73)
Three 18 (15) 14 (19)
More than three 10 (8) 6 (8)
What clinical area was the
trial investigating?
122 73
Cancer 25 (20) 4 (5)
Mental health (including
neurosciences/psychiatry/
psychology)
21 (17) 13 (18)
Orthopedics/rheumatology
(including back pain)
21 (17) 1 (1)
Obstetrics and gynecology 9 (7) 2 (3)
Primary care 8 (7) 13 (18)
Cardiology 5 (4) 4 (5)
Gastroenterology 5 (4) 0 (0)
Incontinence/urology 5 (4) 3 (4)
HIV/AIDS 5 (4) 4 (5)
Other 18 (15) 29 (40)
In what setting did the trial
take place?
122 73
Hospital 64 (53) 29 (40)
General practice 26 (21) 12 (16)
Mixed 16 (13) 17 (23)
Community 7 (6) 15 (21)
Missing 9 (7) 0 (0)
Were there any recruiting
centers outside the UK?
114 73
No 88 (77) 62 (85)
Yes 25 (22) 11 (15)
Missing 1 (1) 0 (0)
Was a clinical trials unit involved? 114 73
Yes 89 (78) 31 (42)
No 25 (22) 40 (55)
Missing 0 (0) 2 (3)
Which body funded the trial? 122 73
UK Medical Research Council (MRC) 73 (64) 41 (56)
UK Health Technology
Assessment (HTA)
41 (36) 31 (43)
Both 0 (0) 1 (100)
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Data extraction
The International Standard Randomised Controlled
Trial Number (ISRCTN) was captured for each trial. For
HTA-funded trials, the original HTA publication was
used. MRC-funded trials were investigated on a case-by
-case basis, where possible using the original study
protocol, clinical report, or trial website found by using
the ISRCTN. For trials where no information could be
found, the principal investigator or trial manager was
contacted.
While the reporting of trials was largely of a good
standard, there were limits on the trial details published.
Occasionally, therefore, we were not able to gather infor-
mation on certain specifics, denoted by the ‘Missing’
values in tables.
Trial recruitment was classed as a ‘success’ if the ori-
ginal or revised recruitment target was met, or if the
trial was stopped early due to an interim analysis. Trials
that were terminated (for example, due to slow recruit-
ment) were classed as failing to recruit.
Where appropriate, χ2 tests and χ2 tests for trend were
used to test for differences between the two study pe-
riods (1994 to 2002 and 2002 to 2008), between trials
with and without a clinical trials unit (CTU), and be-
tween trials that successfully recruited and those that
did not. Categories with insufficient data and categories
corresponding to missing data were excluded from these
tests. Data were collected and analyzed in SPSS version
19 (SPSS Inc., Chicago, IL, USA).
Power calculations
In addition to capturing recruitment, the planned power
for each trial was also captured. Using this along with
the target and achieved recruitment allows the true
achieved power to be calculated for each trial. This will
be performed by simply rearranging and applying the ap-
propriate sample size formula using the proportion of
the target sample size that was actually recruited, and
does not require using any other trial results. The
process for each study is as follows:
1. Assume a planned type I error α of 0.05, and use
the planned sample size n and the planned power 1-β to
determine the approximate standardised effect size δ of
the study using the formula:
δ2 ¼ 2 Z1−α=2 þ Z1−β
 
2. Calculate the proportion π of the planned sample
size n actually recruited to the study
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eters α, δ2 and σ2 and sample size πn using the formula:
1−βð Þachieved ¼ Φ
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
πnδ2
2
s
−Z1−α=2
2
4
3
5
Results
The databases contained 73 trials fulfilling the inclusion
criteria. Figure 1 shows the flow of trials through the re-
view; 31 (43%) were funded by the HTA, 41 (56%) by
the MRC, and 1 (1%) by both bodies.
Trial characteristics
Table 1 summarises the individual characteristics of the tri-
als. The majority were simple parallel group trials (66 (90%))
with the remainder being factorial designs (4 (5%)) or par-
tially randomised patient preference designs (3 (4%)). Ap-
proximately three-quarters of trials had 2 arms (53, (73%)).
The most common clinical areas for the trials were in
mental health (13 (18%)) and primary care (13 (18%)),
which is a slight change from previous findings [1]
where cancer and orthopedics/rheumatology trials wereTable 2 Numerical characteristics of trials
Characteristic Valid n (%) Recruited
successfully (%)
No. of centers:
Total 60 (82) 34 (57)
2 to 5 16 (27) 9 (56)
6 to 10 9 (15) 5 (56)
11 to 20 7 (12) 4 (57)
21 to 50 11 (18) 6 (55)
51 to 100 9 (15) 4 (44)
101+ 8 (13) 6 (75)
Target recruitment:
Total 73 40 (55)
1 to 100 6 (8) 4 (67)
101 to 200 11 (15) 6 (55)
201 to 400 24 (33) 15 (63)
401 to 1,000 22 (30) 10 (46)
1,001+ 10 (14) 5 (50)
Final recruitment
Total 73 40 (55)
1 to 100 7 (10) 1 (14)
101 to 200 14 (19) 8 (57)
201 to 400 24 (33) 14 (58)
401 to 1,000 20 (27) 12 (60)
1,001+ 8 (11) 5 (63)the most prevalent. There was a large variety in the clin-
ical area being investigated, reflected by the large num-
ber of clinical areas labeled as ‘Other’. We also found a
slight decrease in the number of hospital-based trials
(40% vs 53% reported previously [1]) with more
community-based trials (21%, up from 6%).
Recruitment
Target recruitments ranged from 56 to 8,000 partici-
pants, whereas actual recruitment ranged from 44 to
8,164 participants. Information on the distribution of
both target and achieved sample sizes of trials is shown
in Table 2.
Table 3 describes the success of trial recruitment in
comparison to their original targets. The target was only
met in 40 (55%) of trials; meanwhile, 17 (23%) trials
recruited to 80% but less than 100% of their target. This
is an improvement compared to 1994 to 2002, when
only 31% of trials successfully recruited their target
(P value associated with this difference = 0.002). We
also found that fewer trials revised their sample size
than in 1994 to 2002, with only 19% doing so (down
from 34%; P = 0.036). In five (36%) of these, the tar-
get was revised upwards; the remaining nine (64%) ofMean (SD) Median Minimum
to maximum
38.6 (47.9) 15.5 2 to 205
3.4 (1.3) 3.5
7.6 (1.4) 8.0
14.3 (2.7) 13.0
33.2 (8.4) 34.0
68 (12.6) 68.0
139.5 (39.5) 119.0
706.3 (1,098.0) 388.0 56 to 8,000
77.8 (14.1) 78.0
156.8 (30.4) 150.0
315.9 (56.6) 305.0
637.5 (168.5) 595.0
2,776 (1,938.7) 2,250.0
623.7 (1,117.3) 325.0 44 to 8,164
80.3 (36.8) 58.0
160.4 (60.1) 151.0
295.8 (75.6) 284.0
519.2 (313.9) 538.5
2,476.3 (2,269.6) 2,478.5
Table 3 Recruitment in trials
1994 to 2002 2002 to 2008
Total Total P
value
With CTU Without CTU P
valueN n (%) N n (%) N n (%) N n (%)
Was recruitment a success? 122 73 0.002a 31 40 0.235a
Yes 38 (31) 40 (55) 20 (65) 19 (48)
No 84 (69) 33 (45) 11 (36) 21 (53)
Was the recruitment target revised? 122 73 0.036a 31 40 0.1183a
Yes 42 (34) 14 (19) 3 (10) 11 (28)
No 76 (62) 56 (77) 27 (87) 28 (70)
Missing 4 (3) 3 (4) 1 (3) 1 (3)
Final recruitment figure
Original target: 122 73 <0.001b 31 40 <0.001b
≥100% 38 (31) 40 (55) 20 (65) 19 (48)
≥80% but <100% 29 (24) 17 (23) 8 (26) 9 (23)
<80% 55 (45) 16 (22) 3 (10) 12 (30)
Revised target: 42 14 0.021b 3 11 N/Ab
≥100% 19 (45) 10 (71) 2 (67) 8 (73)
≥80% but <100% 15 (36) 3 (21) 0 (0) 3 (27)
<80% 8 (19) 1 (7) 1 (33) 0 (0)
aP values calculated using χ2 tests, excluding missing categories.
bP values calculated using χ2 tests for trend; in the final case counts were too small to perform tests.
CTU, clinical trials unit; N/A, not applicable.
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was met in the majority (10 (71%)) of trials in which
it was revised, another improvement since the previ-
ous study period (19 (45%)).
The planned size of a trial appears to have a slight
negative effect on the success of recruitment, but the ef-
fect is less pronounced than may be imagined: trials re-
quiring over 1,000 participants recruit successfully 50%
of the time, compared to trials requiring 100 to 200 par-
ticipants 55% of the time, and 1 to 100 people 67% of
the time. Some categories also contained few studies, so
may not be representative of the success of all trials.
The impact of clinical trials units (CTUs) on trials is
positive. A total of 31 (42%) trials had CTUs involved,
down from 78% in 1994 to 2002 [3]. Of these 31, 20
(65%) recruited successfully, while trials without CTUs
successfully recruited only 48% of the time (19 trials).
Table 4 shows how other trial characteristics affected
the recruitment of trials. MRC-funded trials appear to
recruit successfully more often than HTA-funded trials
(25 (61%) compared to 14 (45%)) although the difference
is not statistically significant (P = 0.270). The clinical
area of a trial, however, does seem to influence recruit-
ment success: eight (62%) mental health trials recruited
successfully compared to only three (23%) primary care
trials. However, the sample size for the majority of these
categories is too small to perform meaningful statistical
tests. Trials with ≤16 centers (the median number ofcenters) did not recruit any more successfully than those
with >16 centers (57% vs 57%).
Three (4%) trials had unscheduled trial terminations.
One was halted for ethical reasons discovered during the
trial (another study showing negative results was pub-
lished during the trial and the intervention was deemed to
be ineffective; at this point the target sample size had not
been reached) and two due to slow recruitment. These
were all coded as being unsuccessful in recruitment.
Extensions
Table 5 summarises the number of extensions given to
trials. Just over half (39 (53%)) of trials had no extension.
Those that did largely received time (22 (30%)) or time
and grant (10 (14%)) extensions. Only a single (1%) trial
received a grant extension alone. These data were miss-
ing for one (1%) trial. A total of 20 (64%) trials funded
by the HTA required an extension of some kind, com-
pared to only 12 (29%) of trials funded by the MRC, a
statistically significant difference (P <0.01).
Not all studies reported whether they received an ex-
tension. Where an extension was not reported we
contacted the trial’s chief investigator as identified
through the ISRCTN database; this was necessary for
eight trials, and in one case we did not get a reply. This
was coded as missing in the database.
These data are simplified in Figure 2, where all exten-
sions have been grouped together. In all, 33 (45%) trials
Table 4 How factors affected recruitment
Factor Was recruitment a success?
Yes, n (%) No, n (%) P value
Funding body: 0.182a,b
UK Medical Research
Council (MRC)
25 (61) 16 (39)
UK Health Technology
Assessment (HTA)
14 (45) 17 (55)
Both 1 (100) 0 (0)
Setting: 0.970a
Hospital 16 (55) 13 (45)
General practice 6 (50) 6 (50)
Mixed 10 (59) 7 (41)
Community 8 (53) 7 (47)
Clinical area:
Cancer 3 (75) 1 (25)
Mental health (including
neurosciences/psychiatry/
psychology)
8 (62) 5 (39)
Orthopedics/rheumatology
(including back pain)
1 (100) 0 (0)
Obstetrics and gynecology 1 (50) 1 (50)
Primary care 3 (23) 10 (77)
Cardiology 1 (25) 3 (75)
Incontinence/urology 3 (100) 0 (0)
HIV/AIDS 3 (75) 1 (25)
Other 17 (59) 12 (41)
Number of centers:
≤16 17 (57) 13 (43)
>16 17 (57) 13 (43)
Missing 6 7
aP values calculated using χ2 tests without continuity corrections.
b‘Both’ column excluded from χ2 test due to low counts.
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their target. A total of 39 (53%) trials did not receive an
extension; of these, 21 (54%) recruited successfully.
Hence, trials receiving extensions are equally likely to re-
cruit to 100% of their target sample size as those notTable 5 Extensions to trials
Was an extension
granted and if so,
what type?
1994 to 2002 2002 to 2008
Total Total With
N n (%) N n (%) N
122 73 31
No 57 (47) 39 (53)
Time extension 15 (12) 22 (30)
Grant extension 8 (7) 1 (1)
Time + grant extension 42 (34) 10 (14)
Missing 0 (0) 1 (1)
CTU, clinical trials units; HTA, Health Technology Assessment; MRC, Medical Researcreceiving extensions; however, they are more likely to re-
cruit at least 80% of their target (see Figure 2).
Power
Results from power calculations are summarised in
Table 6 and Figure 3. Only three trials prespecified their
power as any number other than 80% or 90%; one
planned 83%, one 85%, and one 95% power. Of studies
that planned for 90% power, 89% (26) managed to re-
cruit a minimum of 80% of their initially planned sample
size, compared with only 72% (28) of trials planned with
80% power.
Discussion
This review has found improved results compared to the
2006 report by McDonald et al. [1]. Slow or inadequate
recruitment to publicly-funded multicenter RCTs is still
a common problem however, with a large proportion re-
quiring extensions. The previous report looked at trials
recruiting between 1994 and 2002; we updated this to
look at trials recruiting between 2002 and 2008. We
found slightly fewer eligible trials (73, compared to 114;
10.4 per year compared to 12.7 per year).
Over half of trials recruited to 100% of their original
target, up from around one-third in the previous 8 years.
Additionally the proportion of trials failing to recruit
80% of their target in 2002 to 2008 was around one-
fifth; down from 45% in 1994 to 2002. This trend is
promising and could reflect the large amount of work
aimed at increasing recruitment to clinical trials [8], but
the proportion of trials recruiting their target is still con-
siderably less than desirable. More research into both
the reasons behind poor recruitment and methods of
improving it is needed to help increase this over the next
decade.
We found that studies performing sample size calcula-
tions based on 90% power were much more likely to
reach at least the minimum acceptable level of 80%
power than those planned based on 80% power, as
shown in Figure 3. Over half of studies with a planned
power of between 80% and 90% finished with inadequateCTU Without CTU HTA MRC
n (%) N n (%) N n (%) N n (%)
40 31 41
13 (42) 25 (63) 11 (36) 28 (68)
14 (45) 7 (18) 17 (55) 4 (10)
0 (0) 1 (3) 0 (0) 1 (2)
4 (13) 6 (15) 3 (10) 7 (17)
0 (0) 1 (3) 0 (0) 1 (2)
h Council.
Figure 2 Recruitment by extension status.
Table 6 Planned and true power of trials
Planned power
80% to 89% 90%+ Missing
N n (%) N n (%) N
True power 39 28 6
90%+ 2 (7) 10 (53)
80% to 89% 12 (43) 4 (21)
<80% 14 (50) 5 (26)
Missing 11 9
Final recruitment 39 28 6
≥100% 22 (56) 16 (57)
≥80% but less than 100% 6 (15) 9 (32)
<80% 11 (28) 3 (11)
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more likely to complete with at least 80% power than those
that plan for 80%. Our advice therefore is to design a trial
with as high a power as possible: if the study under-
recruits there is the opportunity to reduce the power to at
least 80% power.
Extensions have become less commonplace, but are
still granted in a large proportion of trials. Figure 2
shows that trials receiving an extension are no more
likely to recruit 100% of their target than those not re-
ceiving one; they are however more likely to recruit be-
tween 80% and 100% of their target. That is not to say
that extensions have no use, as extensions more than
likely facilitated the recruitment achieved.
The proportion of publicly-funded trials using CTUs
has decreased compared to pre-2002. However, the HTA
now requires evidence of CTU involvement when
funding trials, which could have caused this proportion
to have increased since 2008. CTU involvement did not
reduce the prevalence of extension requests, but was as-
sociated with improved recruitment to trials.
Trials with CTUs appear to obtain extensions more
often than trials without (58% compared to 36%). This
could be because slow recruitment in CTU studies is
due to factors beyond the control of the trial team, or it
could be because trials involving CTUs are reported
more thoroughly and are less likely to omit the presence
of an extension. It appears that the HTA are morewilling to provide extensions than the MRC (64% of
HTA trials were given an extension of some kind, com-
pared to 32% of MRC trials), perhaps due to the type of
trials they tend to fund.
There have been many reviews of methods to improve
recruitment to trials, particularly in the last 10 years.
Watson and Torgerson [5] undertook a systematic re-
view of RCT trialing methods, with the aim of identify-
ing effective strategies. They found that there were very
few such trials, but specific strategies to help recruit-
ment included not blinding, educating clinicians, using
culturally specific designs and incentives for participants.
Figure 3 Achieved power of studies by planned power (missing data omitted).
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current RCTs, more advanced statistical methods should
be considered in trial planning and analysis. One particu-
larly attractive and increasingly popular strategy is the use
of adaptive designs. Such designs provide opportunities to
determine the progress of trials, allowing for reassessment
of the assumptions in made in the design of a trial as well
as to make an assessment of efficacy and futility. They
have the potential to save both time and money [9].
One strength of this investigation is its adherence to the
methods undertaken by McDonald et al. [1] in their previ-
ous study, which allows for a comparison of the results.
However, a limitation of this study is the quality of data.
All data were retrieved from online reports of HTA-funded
and MRC-funded trials, and as such was not always
complete. For example, not all studies reported where they
had received an extension. It should be noted though that
recruitment rates are specified in the Consolidated Stan-
dards of Reporting Trials (CONSORT) statement as being
required [10], which facilitated extraction of these data.
In undertaking this study we found two studies that
were halted due to a significant finding of efficacy in a
planned interim analysis by their data monitoring com-
mittee, which were subsequently coded as a successful
recruitment. As noted in an earlier section there were
also two trials that stopped early due to slow recruit-
ment, and another due to ethical reasons; all three of
these were coded as a failure to recruit. However, it is
quite possible that the studies halted due to efficacy werestill under their recruitment target; similarly that the
study stopped due to ethical reasons was recruiting to
their target. These trials highlight a difficulty of this re-
search where limited information was available on trials,
requiring some discretion on the authors’ part.
Conclusions
This study was performed as an update to the 2006 re-
view by McDonald et al. [1]. We found that although re-
cruitment rates have improved since 1994 to 2002 they
are still low, with only around half recruiting to their
target. Additionally extensions are still widely requested
(and granted), with almost one-third of trials receiving
an extension of some kind (down from around half in
1994 to 2002). Trials that fail to reach recruitment tar-
gets are less likely to answer their objectives and so
could have their ethics questioned.
There is clearly room for research on both ways of im-
proving recruitment, and ways of monitoring and man-
aging low recruitment. Involving a CTU in a trial
appears to play a role in increasing recruitment to trials.
We would recommend that adaptive designs that enable
reassessment of the trial design assumptions are more
commonly undertaken in public-funded trials.
Trials designed with 80% power are over twice as likely
not to recruit at least 80% of their target sample size as
those designed with 90%; indeed, planning a trial with
80% power could be seen as a marker for a study that
may fail to recruit. While the commonly used powers of
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possible trials are designed with higher power; this way,
trials can consider sacrificing some power if recruitment
is not as successful as expected.
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